Alector, Inc. (NASDAQ:ALEC) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. raised its position in shares of Alector, Inc. (NASDAQ:ALEC) by 3.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 61,239 shares of the company’s stock after purchasing an additional 2,120 shares during the period. Mirae Asset Global Investments Co. Ltd. owned 0.06% of Alector worth $489,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC increased its holdings in shares of Alector by 58.3% during the third quarter. FMR LLC now owns 12,172,045 shares of the company’s stock valued at $78,875,000 after purchasing an additional 4,481,420 shares during the period. Euclidean Capital LLC increased its stake in Alector by 33.3% during the 3rd quarter. Euclidean Capital LLC now owns 1,307,858 shares of the company’s stock valued at $8,475,000 after buying an additional 326,964 shares during the period. Jacobs Levy Equity Management Inc. raised its position in shares of Alector by 33.5% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 778,077 shares of the company’s stock worth $5,042,000 after buying an additional 195,411 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Alector in the 3rd quarter worth approximately $1,103,000. Finally, TD Asset Management Inc boosted its holdings in shares of Alector by 957.2% in the third quarter. TD Asset Management Inc now owns 119,138 shares of the company’s stock valued at $772,000 after acquiring an additional 107,869 shares in the last quarter. 85.83% of the stock is owned by institutional investors and hedge funds.

Alector Price Performance

Shares of ALEC opened at $5.25 on Friday. Alector, Inc. has a 12-month low of $3.66 and a 12-month high of $9.06. The stock has a market capitalization of $502.68 million, a P/E ratio of -3.39 and a beta of 0.79. The firm’s 50 day moving average is $6.07 and its 200-day moving average is $6.16.

Alector (NASDAQ:ALEC) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.31. Alector had a negative net margin of 134.34% and a negative return on equity of 77.15%. The firm had revenue of $15.19 million for the quarter, compared to analyst estimates of $8.35 million. As a group, equities research analysts forecast that Alector, Inc. will post -1.89 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Arnon Rosenthal sold 18,837 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $6.92, for a total value of $130,352.04. Following the completion of the transaction, the chief executive officer now owns 2,000,380 shares in the company, valued at approximately $13,842,629.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Marc Grasso sold 5,716 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $6.92, for a total transaction of $39,554.72. Following the sale, the chief financial officer now owns 144,957 shares in the company, valued at $1,003,102.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Arnon Rosenthal sold 18,837 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $6.92, for a total transaction of $130,352.04. Following the completion of the sale, the chief executive officer now owns 2,000,380 shares of the company’s stock, valued at approximately $13,842,629.60. The disclosure for this sale can be found here. Insiders have sold 30,554 shares of company stock worth $211,434 in the last three months. 14.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $41.00 target price on shares of Alector in a report on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $14.50.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.